H.C. Wainwright Reiterates Buy Rating on BlossomHill Therapeutics (BLSM) Sep 30, 2026 07:18AM
BlossomHill Therapeutics (BLSM) PT Raised to $40 at Guggenheim Sep 21, 2026 06:40AM
LifeSci Capital Starts BlossomHill Therapeutics (BLSM) at Outperform Sep 1, 2026 06:20AM
H.C. Wainwright Starts BlossomHill Therapeutics (BLSM) at Buy Sep 1, 2026 06:13AM
Guggenheim Starts BlossomHill Therapeutics (BLSM) at Buy Sep 1, 2026 06:08AM


Sep 1, 2026 02:43AM JPMorgan Starts BlossomHill Therapeutics (BLSM) at Overweight
Aug 3, 2026 06:11AM BlossomHill Therapeutics files for Nasdaq IPO at up to $17 per share
Jul 17, 2026 06:05AM BlossomHill Therapeutics files for Nasdaq IPO under ticker BLSM